^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Genomic biomarkers of response to lenvatinib/pembrolizumab (Len/Pembro) in patients with advanced renal cell carcinoma.

Published date:
02/14/2020
Excerpt:
This study is investigating the genomic components of tumor antigen presentation in ICB-naïve patients who have RCC and are treated with len/pembro...Loss-of-function mutations in PBRM1 (PBRM1 LOF) trended toward improved PFS...PBRM1 mutation may be associated with improved PFS
Trial ID: